|
|
 |
|
Viewing report
|
|
|
|
Cell Signalling Pathways - Productive Sources of Pharmaceutical Targets
Drug and Market Development Publishing, May 2004, Pages: 270
Cell signalling pathways are responsible for the normal function of all organ systems through controlling the interactions between and within cells. The cause of many diseases is the interruption of one or more of these pathways. Therefore, identifying key pathway components could be logical targets for the development of pharmaceuticals to treat these diseases.
Cell signalling pathways contain protein families that are targets for many highly successful drugs on the market today. Kinases, G-Protein Coupled Receptors (GPCRs), and nuclear receptors contained within cell signalling pathways have all been successfully modulated by drugs for the treatment of major disease, including cancer, diabetes, and inflammation. As the understanding of the molecular interactions within cell signalling pathways are more completely understood, new, highly specific drug targets will most likely be discovered, spurring the development of the next generation of targeted pharmaceuticals.
Scope
Our Cell Signalling Pathways Report provides an overview of major signalling pathways. A description of the individual components that have the potential to be exploited as drug targets are reviewed and drug candidates in development against many of these targets are analyzed. The Report also examines the successes and failures of drug development efforts thus far. In addition, 39 companies active in the cell signalling market are profiled in-depth.
Market Opportunities
- Develop new drugs that specifically target key components of cell signalling pathways in order to treat disease as effectively as current drugs on the market, but with reduced side effects.
- Build upon the success of current drugs targeting cell signalling pathways protein families through identifying the functions of those 'orphan proteins' that are still unknown, which could lead to the development of new and effective therapies.
- Design and perform clinical trials that accurately reflect drug performance - preventing expensive, late-stage failures - through clearly understanding the limitations of cytostatic agents.
- Bring a biological drug to market quicker and cheaper through solid industry partnerships and a clear understanding of the roles of the FDA/CBER.
Key Reasons to Buy
- Get an in-depth look at cell signalling pathways via a concise overview of how they are implicated in significant human diseases, including cancer, inflammation & autoimmunity, and metabolic syndrome.
- Pinpoint the full market potential for cell signalling from a comprehensive assessment of the magnitude and impact of diseases caused by aberrant cell signalling and the deficiencies of currently marketed therapies.
- Identify the commercial opportunities for drugs directed toward abnormal cell signalling with a thorough review of specific pathway components that have the most potential as pharmaceutical targets.
- Obtain a complete and extensive appraisal of the development status of drug candidates currently in clinical development that target components of cell signalling pathways, including a discussion of reported clinical trial results.
- Look inside 39 companies active in cell signalling pathways, including their products and services, financial standing, key developments, alliances, and more.
Customers who bought this item also bought
Dendritic Cells: Targets for Immunotherapy
2004 HDL CHOLESTEROL - 5th Annual Metabolic Pathways and Drug Targets
Systems Biology - Key to Unlocking the Value within the Omics Revolution
Phosphatases: Emerging Role in Signal Transduction, Human Therapeutics, & As Drug Targets
Protein-Protein Interactions as Drug Targets- Focusing On Cell Circuitry
Mammalian Cell Culture: Production Technologies and Market Overview
Rheumatoid arthritis: Emerging drug discovery targets and therapeutic candidates
Promising Drug Discovery Tools in Antifungal & Status on Emerging Novel Targets
|
|
|
|
